Cadrenal Therapeutics, Inc.

Disclosure of Material Event

On August 12, 2026, the Board appointed Quang X. Pham as our Chief Business Officer. In addition to his position as Chief Executive Officer, Mr. Pham has been performing the duties and responsibilities customarily performed by a Chief Business Officer, including business development and commercial operations. The Board determined to formally appoint Mr. Pham as Chief Business Officer in recognition of the additional duties he has been performing and to authorize him to continue to perform such duties in that capacity. Mr. Pham will not receive any additional compensation, benefits, or other remuneration for serving in the role of Chief Business Officer beyond his existing compensation, benefits, and other remuneration as our Chief Executive Officer.

Insider Trading Arrangements

During the six months ended June 30, 2026, no officer or director of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “nonRule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as set forth below.

During the fiscal quarter ended June 30, 2026, Quang X. Pham, our Chief Executive Officer, paused a Rule 10b5-1 trading arrangement (within the meaning of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended) for the sale of shares of our Common Stock that was originally adopted on September 23, 2025, to be effective on December 23, 2025 (the “Trading Plan”). Mr. Pham suspended the Trading Plan on June 30, 2026, in accordance with the terms thereof, which allows for the Trading Plan to be suspended in the event that a sale of shares under the Trading Plan should not be effected due to a contractual restriction. Mr. Pham entered into a lock-up agreement in connection with the PIPE Transaction, pursuant to which he agreed to be subject to a lock-up for a period of 60 days following the Effective Date (July 20, 2026). The Trading Plan has a scheduled expiration date of September 30, 2026 and provides for the sale of up to a maximum of 137,356 shares of our Common Stock in the aggregate. A total of 39,856 shares of Common Stock remained to be sold under the Trading Plan prior to its suspension.